Your browser doesn't support javascript.
loading
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.
López-Iglesias, Ana-Alicia; Herrero, Ana B; Chesi, Marta; San-Segundo, Laura; González-Méndez, Lorena; Hernández-García, Susana; Misiewicz-Krzeminska, Irena; Quwaider, Dalia; Martín-Sánchez, Montserrat; Primo, Daniel; Paíno, Teresa; Bergsagel, P Leif; Mehrling, Thomas; González-Díaz, Marcos; San-Miguel, Jesús F; Mateos, María-Victoria; Gutiérrez, Norma C; Garayoa, Mercedes; Ocio, Enrique M.
Afiliação
  • López-Iglesias AA; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Herrero AB; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Chesi M; Comprehensive Cancer Center, Mayo Clinic, Arizona, USA.
  • San-Segundo L; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • González-Méndez L; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Hernández-García S; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Misiewicz-Krzeminska I; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Quwaider D; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Martín-Sánchez M; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Primo D; Vivia Biotech, Madrid, Spain.
  • Paíno T; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain. tpaino@usal.es.
  • Bergsagel PL; Comprehensive Cancer Center, Mayo Clinic, Arizona, USA.
  • Mehrling T; Mundipharma-EDO GmbH, Basel, Switzerland.
  • González-Díaz M; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • San-Miguel JF; Center for Applied Medical Research (CIMA), IDISNA, University Clinic of Navarra, Pamplona, Spain.
  • Mateos MV; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Gutiérrez NC; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Garayoa M; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
  • Ocio EM; University Hospital of Salamanca (IBSAL) & Cancer Research Center (IBMCC-CSIC-USAL), Salamanca, Spain.
J Hematol Oncol ; 10(1): 127, 2017 06 20.
Article em En | MEDLINE | ID: mdl-28633670
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzimidazóis / Dano ao DNA / Reparo do DNA / Inibidores de Histona Desacetilases / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Benzimidazóis / Dano ao DNA / Reparo do DNA / Inibidores de Histona Desacetilases / Mieloma Múltiplo / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Hematol Oncol Assunto da revista: HEMATOLOGIA / NEOPLASIAS Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Espanha